CO6190516A2 - Pirazoles sustituidos composiciones que los contienen procedimientos de fabricacion y utilizacion - Google Patents

Pirazoles sustituidos composiciones que los contienen procedimientos de fabricacion y utilizacion

Info

Publication number
CO6190516A2
CO6190516A2 CO09046036A CO09046036A CO6190516A2 CO 6190516 A2 CO6190516 A2 CO 6190516A2 CO 09046036 A CO09046036 A CO 09046036A CO 09046036 A CO09046036 A CO 09046036A CO 6190516 A2 CO6190516 A2 CO 6190516A2
Authority
CO
Colombia
Prior art keywords
substituted
group
alkyl
heteroaryl
aryl
Prior art date
Application number
CO09046036A
Other languages
English (en)
Inventor
Kirsten Bjergarde
Mark Dodson
Jacques Mauger
Anil Nair
Marcel Patek
Michel Tabart
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CO6190516A2 publication Critical patent/CO6190516A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Abstract

1.- Producto de fórmula general (I) siguiente:en la que:1) A y Ar se seleccionan independientemente del grupo constituido por: arilo, heteroarilo, arilo sustituido, heteroarilo sustituido; 2) L se selecciona del grupo constituido por: NH-CO-NH y O-CO-NH; 3) R1 se selecciona del grupo constituido por : H, R6, COR6, SO2R6, en el que R6 se elige entre H, OR7, NR8R9, alquilo, cicloalquilo, heterociclilo, heterociclilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, en el que R7 se elige entre H, fenilo, alquilo, y en el que R8 y R9 se seleccionan independientemente del grupo constituido por H, alquilo, cicloalquilo, heterociclilo, heterociclilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido o bien R8 y R9 están unidos entre sí para formar un ciclo saturado de 5 a 8 eslabones que contiene de 0 a 3 heteroátomos elegidos entre O, S y N; 4) X se selecciona del grupo constituido por: O y NH; 5) R3 se selecciona del grupo constituido por : H, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido; 6) R4a se selecciona del grupo constituido por : H o alquilo(C1-C4); 7) R4b se selecciona del grupo constituido por : H o alquilo(C1-C4);8) R5 se selecciona del grupo constituido por: H, halógeno, R10, CN, O(R10), OC(O)(R10), OC(O)N(R10)(R11), OS(O2)(R10), N(R10)(R11), N=C(R10)(R11), N(R10)C(O)(R11), N(R10)C(O)O(R11), N(R12)C(O)N(R10)(R11), N(R12)C(S)N(R10)(R11), N(R10)S(O2)(R11), C(O)(R10), C(O)O(R10), C(O)N(R10)R11), C(=N(R11))(R10), C(=N(OR11(R10), S(R10), S(O)(R10), S(O2)(R10), S(O2)O(R10), S(O2)N(R10)(R11); en el que cada R10, R11, R12 se selecciona independientemente del grupo constituido por H, alquilo, alquileno, alquinilo, arilo, heteroarilo, cicloalquilo, heterociclilo, alquilo sustituido, alquileno sustituido, alquinilo sustituido, arilo sustituido, heteroarilo sustituido, cicloalquilo sustituido y heterociclilo sustituido.
CO09046036A 2006-11-10 2009-05-07 Pirazoles sustituidos composiciones que los contienen procedimientos de fabricacion y utilizacion CO6190516A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0609812A FR2908409B1 (fr) 2006-11-10 2006-11-10 Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
CO6190516A2 true CO6190516A2 (es) 2010-08-19

Family

ID=38169388

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09046036A CO6190516A2 (es) 2006-11-10 2009-05-07 Pirazoles sustituidos composiciones que los contienen procedimientos de fabricacion y utilizacion

Country Status (40)

Country Link
US (3) US7989439B2 (es)
EP (1) EP2091920B1 (es)
JP (1) JP5538893B2 (es)
KR (1) KR20090083456A (es)
CN (1) CN101553473B (es)
AR (1) AR063638A1 (es)
AU (1) AU2007327423B2 (es)
BR (1) BRPI0718999A2 (es)
CA (1) CA2667846A1 (es)
CL (1) CL2007003251A1 (es)
CO (1) CO6190516A2 (es)
CR (1) CR10749A (es)
CY (1) CY1116000T1 (es)
DK (1) DK2091920T3 (es)
DO (1) DOP2009000088A (es)
EA (1) EA019454B1 (es)
EC (1) ECSP099312A (es)
ES (1) ES2528385T3 (es)
FR (1) FR2908409B1 (es)
HK (1) HK1137988A1 (es)
HN (1) HN2009000856A (es)
HR (1) HRP20150070T1 (es)
IL (1) IL198328A0 (es)
MA (1) MA30972B1 (es)
MX (1) MX2009004983A (es)
MY (1) MY147502A (es)
NI (1) NI200900078A (es)
NO (1) NO20091990L (es)
NZ (1) NZ576709A (es)
PE (2) PE20121152A1 (es)
PL (1) PL2091920T3 (es)
PT (1) PT2091920E (es)
SI (1) SI2091920T1 (es)
SV (1) SV2009003253A (es)
TN (1) TN2009000155A1 (es)
TW (1) TW200829556A (es)
UA (1) UA97965C2 (es)
UY (1) UY30707A1 (es)
WO (1) WO2008065282A2 (es)
ZA (1) ZA200903560B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
TWI532725B (zh) * 2010-01-26 2016-05-11 賽諾菲阿凡提斯公司 經氧取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
TWI523844B (zh) * 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
CN102432639B (zh) * 2011-09-30 2013-11-06 山东大学 1-(2-羟基-3-(苯氨基)丙基)-3-二茂铁基-1h-吡唑-5-甲酸乙酯化合物及其应用
ES2625944T3 (es) 2012-11-02 2017-07-21 Pfizer Inc. Inhibidores de tirosina cinasa de Bruton
CA2976766A1 (en) * 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2445357A1 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
CN1809557B (zh) * 2003-04-16 2012-07-04 阿斯利康(瑞典)有限公司 化合物
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
PL2256106T3 (pl) * 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
EP1781653A1 (en) * 2004-07-05 2007-05-09 Astex Therapeutics Limited 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
WO2006018662A2 (en) * 2004-08-16 2006-02-23 Prosidion Limited Aryl urea derivatives for treating obesity
JP2008526723A (ja) * 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
US20080161355A1 (en) * 2005-01-21 2008-07-03 Astex Therapeutics Limited Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
EP1683796A1 (en) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
PE20081162A1 (es) 2008-10-02
WO2008065282A3 (fr) 2008-07-31
CL2007003251A1 (es) 2009-08-07
CR10749A (es) 2009-07-23
US8420824B2 (en) 2013-04-16
AU2007327423B2 (en) 2012-09-06
IL198328A0 (en) 2010-02-17
TN2009000155A1 (fr) 2010-10-18
CY1116000T1 (el) 2017-01-25
NI200900078A (es) 2010-01-27
AU2007327423A1 (en) 2008-06-05
TW200829556A (en) 2008-07-16
HK1137988A1 (en) 2010-08-13
NZ576709A (en) 2011-08-26
HN2009000856A (es) 2011-10-19
EP2091920A2 (fr) 2009-08-26
EP2091920B1 (fr) 2014-10-22
EA200970472A1 (ru) 2009-10-30
DK2091920T3 (en) 2015-01-26
CA2667846A1 (fr) 2008-06-05
PL2091920T3 (pl) 2015-04-30
ZA200903560B (en) 2010-08-25
SV2009003253A (es) 2009-10-27
MA30972B1 (fr) 2009-12-01
US20110237641A1 (en) 2011-09-29
HRP20150070T1 (hr) 2015-02-27
MY147502A (en) 2012-12-14
NO20091990L (no) 2009-06-02
PE20121152A1 (es) 2012-09-07
JP5538893B2 (ja) 2014-07-02
CN101553473B (zh) 2013-06-05
ES2528385T3 (es) 2015-02-09
WO2008065282A2 (fr) 2008-06-05
BRPI0718999A2 (pt) 2014-02-25
EA019454B1 (ru) 2014-03-31
DOP2009000088A (es) 2013-06-15
UA97965C2 (ru) 2012-04-10
US20090291984A1 (en) 2009-11-26
PT2091920E (pt) 2015-02-05
FR2908409A1 (fr) 2008-05-16
ECSP099312A (es) 2009-06-30
SI2091920T1 (sl) 2015-02-27
JP2010509297A (ja) 2010-03-25
AR063638A1 (es) 2009-02-04
MX2009004983A (es) 2009-05-22
US7989439B2 (en) 2011-08-02
FR2908409B1 (fr) 2009-01-09
UY30707A1 (es) 2008-07-03
US8410286B2 (en) 2013-04-02
US20110237801A1 (en) 2011-09-29
KR20090083456A (ko) 2009-08-03
CN101553473A (zh) 2009-10-07

Similar Documents

Publication Publication Date Title
CO6190516A2 (es) Pirazoles sustituidos composiciones que los contienen procedimientos de fabricacion y utilizacion
PE20081448A1 (es) Inhibidores de transcriptasa inversa no nucleosidicos
AR068074A1 (es) Compuestos de piperazina con accion herbicida. proceso de preparacion
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
AR054799A1 (es) Derivados de oxindol
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
PE20130647A1 (es) Indoles
CO6160235A2 (es) Isoxazolinas insecticidas
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
AR040668A1 (es) Piridinas y pirimidinas 4- trifluormetilpirazolil sustituidas
ECSP10010473A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
PE20020354A1 (es) Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
PE20091236A1 (es) Derivados de pirimidina como immunomoduladores de tlr7
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
RU2009141982A (ru) Пиримидиновые производные
EA200870191A1 (ru) Новые производные циклической мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназ
PE20091426A1 (es) Compuestos de piridina

Legal Events

Date Code Title Description
FG Application granted